PARP3 inhibitors to improve the treatment of metastatic breast cancer

PARP3 inhibitors to improve the treatment of metastatic breast cancer

Dr. Lawrence Panasci, MD, Jewish General Hospital, Lady Davis Institute for Medical Research Montreal, Quebec
PARP3 inhibitors to improve the treatment of metastatic breast cancer

In Canada, breast cancer is the most common cancer and the 2nd leading cause of death among women. Major advancements have been made in the treatment of adjuvant and metastatic breast cancer with various types of chemotherapy in the last 30 years but treatment options have plateaued in the last 15-20 years for some specific subtypes (hormone receptor negative and HER2 receptor negative) of breast cancer. As such, there is an urgent need to improve chemotherapy to treat women with breast cancer. Using breast cancer cell lines, we will determine the role of a PARP3 inhibitor in drug resistance and its efficacy in combination with conventional treatments utilizing biochemical and DNA techniques in test tubes and animal models. Our results could represent a breakthrough treatment in breast cancer especially breast cancer subtype not eligible for treatment with hormonal or HER2 specific therapies.

Close Menu